



Docket No. CEN 249 CIPNP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Jill Giles-Komar et al

Serial No. : 10/720,323

Art Unit:

Filed : November 24, 2003


Examiner:

For : ANTI-DUAL INTEGRIN ANTIBODIES, COMPOSITIONS,  
METHODS AND USES.

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P. O. Box 1450 on

19  
APRIL 15, 2004  
(Date of Deposit)

KENNETH J. DOW  
(Name of applicant, assignee, or Registered Representative)

  
(Signature)

19  
APRIL 15, 2004  
(Date of Signature)

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/CEN249CIPNP/KD the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/CEN249CIPNP/KD the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☒ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner from the Patent Application SN09/920,267, copies are not enclosed herewith.

☒ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN249CIPNP/KD. This form is submitted in triplicate.


Respectfully submitted,



Kenneth J. Dow  
Reg. No. 32,890  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(610) 651-7422  
DATED: APRIL 17, 2004





# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

<b>Application Number</b>	10/720,323
<b>Filing Date</b>	November 24, 2003
<b>First Named Inventor</b>	Jill Giles-Komar
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	CEN 249 CIPNP

**U.S. PATENT DOCUMENTS**

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature	Date Considered
--------------------	-----------------

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*EXAMINER: Initial if reference considered. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



(use as many sheets as necessary)

Sheet 3 of 3

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
It contains a valid OMB control number.

<b>Application Number</b>	10/720,323
<b>Filing Date</b>	November 24, 2003
<b>First Named Inventor</b>	Jill Giles-Komar
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	CEN 249 CIPNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			T <sup>2</sup>
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
		TAM et al, "Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates equivalent affinity and functional blockade of glycoprotein lib/IIla and $\alpha_v\beta_3$ Integrins," vol. 98, No. 11, 09-15-1998, pages 1098-1091, USA.	
		TRIKHA et al, "A potential new application for a cardiovascular drug: Role for ReoPro (Abciximab), an inhibitor of GIIIB/IIIA and $\alpha_v\beta_3$ integrins, as an anti-cancer agent," Proceedings of the American Association for Cancer Research, vol. 41, March 2000, page 577, USA.	
		SUZUKI et al, "cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors," Cell Biology, November 1986, pages 8614-8618, vol. 83, Proc. National Academy Science, USA.	
		LEHMANN ET AL, "A monoclonal antibody inhibits adhesion to fibronectin and bitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha_v\beta_3$ , $\alpha_v\beta_5$ , $\alpha_v\beta_6$ ," Cancer Research, 1994, pages 2102-2107, Vol. 52, USA.	
		GUNTHER CASTL, THOMAS HERMANN, MCIAHEL STEURER, JORG ZMIJA, EBERHARD GUNSILIUS, CLEMENS UNGER, AND ANDREA KRAFT, "Angiogenesis as a target for tumor treatment," Oncology, 1997, 177-84, Vol. 54.	
		BRIAN P. ELICEIRI AND DAVID A. CHERESH, "The role of $\alpha_v$ integrins during angiogenesis: insights into potential mechanisms of action and clinical development," The Journal of Clinical Investigation, May 1999, 1227-30, vol. 103, no. 9.	
		MARTIN FRIEDLANDER, PETER C. BROOKS, ROBERT W. SHAFFER, CHRISTINE M. KINCAID, JUDITH A. VARNER, AND DAVID A. CHERESH, "DEFINITION OF TWO ANGIOGENIC PATHWAYS BY DISTINCT ALPHA-V INTEGRINS," Science, Dec. 1, 1995, 1500-2, vol. 270.	
		LISA D. TAYLOR, CONDIE E. CARMACK, DENNIS HUSZAR, KAY M. HIGGINS, ROSHANAK MASHAYEKH, GETACHEW SEQUAR, STEPHEN R. SCHRAMM, CHIUNG-CHI KUO, SUSAN L. O'DONNELL, ROBERT M. KAY, OLIVE S. WOODHOUSE, AND NILS LONBERG, "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," International Immunology, 1994; 579-91, vol. 6 no. 4, Oxford University Press.	
		NILS LONBERG, LISA D. TAYLOR, FIONA A. HARDING, MARY TROUNSTINE, KAY M. HIGGINS, STEPHEN R. SCHRAMM, CHIUNG-CHI KUO, ROSHANAK MASHAYEKH, KATHRYN WYMORE, JAMES G. MCCABE, DONNA MUNOZ-O'REGAN, SUSAN L. O'DONNELL, ELIZABETH S. G. LAPACHET, TASH BENGOCHEA, DIANNE M. FISHWILD, CONDIE E. CARMACK, ROBERT M. KAY AND DENNIS HUSZAR, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Nature, April 28, 1994, 856-9, vol. 368.	
		MICHAEL NEUBERGER, "Generating high-avidity human Mabs in mice," Nature Biotechnology, July 1996, 826, vol. 14.	
		DIANNE M. FISHWILD, SUSAN L. O'DONNELL, TASH BENGOCHEA, DEBRA V. HUDSON, FIONA HARDING, SUSAN L. BERNHARD, DEBBIE JONES, ROBERT M. KAY, KAY M. HIGGINS, STEPHEN R. SCHRAMM, AND NILS LONBERG, "High-avidity human IgG-kappa monoclonal antibodies from a novel strain of minilocus transgenic mice," Nature Biotechnology, July 1996, 845-51, vol. 14.	
		ELIZABETH A. WAYNER, ROBERT A. ORLANDO AND DAVID A. CHERESH, "Integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface," J. Cell Biology, May 1991, 919-29, vol. 113, no. 4.	
		JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SIMON L. GOODMAN AND IAN R. HART, "Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin," J. of Cell Science, 1995, 1227-38, vol. 108.	
		DAVID A. CHERESH AND ROBERT C. SPIRO, "Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor," J. of Biological Chemistry, Dec. 25 1987, 17703-11, vol. 262, no. 36.	
		HANS KEMPERMAN, YVONNE M. WIJNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells: Adhesion to Fibronectin is Mediated Solely by Small Amounts of alpha v beta 6, and alpha v beta 5 is Codistributed with Actin Fibers," Experimental Cell Research, 1997, 156-64, vol. 234.	
		MAXIME LEHMANN, CHANTAL RABENANDRASANA, RICHARD TAMURA, JEAN-CLAUDE LISSITZKY, VITO QUARANTA, JACQUES PICHON, AND JACQUES MARVALDI, "A Monoclonal Antibody Inhibits Adhesion to Fibronectin and Vitronectin of a Colon Carcinoma Cell Line and Recognizes the Integrins $\alpha_v\beta_3$ , $\alpha_v\beta_5$ , and $\alpha_v\beta_6$ ," Cancer Research, Apr 15 1994, 2102-07, vol. 54.	